Nail Disorders: Dermatological Assessment and Care

Nail disorders encompass a broad spectrum of structural, infectious, inflammatory, and neoplastic conditions affecting the fingernails and toenails. Accurate dermatological assessment matters because nail changes frequently serve as visible markers of systemic disease, localized infection, or malignancy that requires prompt attention. This page covers the major classifications of nail pathology, the clinical mechanisms behind common presentations, typical patient scenarios, and the decision thresholds that determine when specialist referral or biopsy is warranted. For a broader orientation to dermatological care, the National Dermatology Authority home page provides context across the full scope of skin and appendage medicine.

Definition and scope

Nail disorders are classified within dermatology as diseases of the nail unit — a structure comprising four distinct anatomical compartments: the nail matrix (which generates the nail plate), the nail bed, the nail folds, and the hyponychium (the keratinized tissue at the free edge). The American Academy of Dermatology (AAD) recognizes nail pathology as a subspecialty domain requiring specific training in dermoscopy, onychoscopy, and nail biopsy technique.

The International Classification of Diseases, Tenth Revision (ICD-10), published by the World Health Organization, assigns nail disorders to the L60–L63 code block and separately flags nail findings associated with systemic disease under codes such as L62 (nail disorders in diseases classified elsewhere). This classification framework establishes that nail pathology is neither exclusively cosmetic nor exclusively infectious — it spans inflammatory dermatoses, fungal infections, trauma responses, benign tumors, and malignant neoplasms.

Onychomycosis — fungal nail infection — is estimated by the AAD to affect approximately 10% of the general US population, making it the single most common nail disorder encountered in clinical dermatology and primary care settings.

How it works

Nail plate formation and disruption

The nail plate grows continuously from the nail matrix at a rate of approximately 3 mm per month for fingernails and 1.5 mm per month for toenails (figures cited in standard dermatology references, including the textbook Nails: Diagnosis, Therapy, Surgery by Scher and Daniel). Disruptions to matrix cell division — whether from inflammation, trauma, systemic illness, or medication toxicity — produce characteristic structural changes in the emerging plate.

The major pathological mechanisms fall into five categories:

  1. Infectious invasion — Dermatophytes (Trichophyton rubrum in the majority of onychomycosis cases), yeasts, and non-dermatophyte molds penetrate the nail unit through the hyponychium or lateral nail folds, causing subungual hyperkeratosis, onycholysis (plate separation from the bed), and discoloration.
  2. Inflammatory matrix damage — Psoriasis, lichen planus, and alopecia areata all involve immune-mediated matrix attack. Nail psoriasis produces pitting (small punctate depressions), oil-drop discoloration, and onycholysis; lichen planus can cause permanent scarring with pterygium formation (see psoriasis types and management for the broader disease context).
  3. Traumatic remodeling — Repetitive microtrauma or acute crush injuries disrupt matrix architecture, producing ridging, melanonychia striata (longitudinal pigmented bands), or subungual hematoma.
  4. Systemic disease signaling — Koilonychia (spoon nails) correlates with iron deficiency anemia; clubbing associates with chronic hypoxia; Beau's lines (transverse grooves) mark periods of systemic stress such as major illness or chemotherapy.
  5. Neoplastic transformation — Subungual melanoma, squamous cell carcinoma, and glomus tumors arise within the nail unit and require biopsy for definitive diagnosis.

Common scenarios

Onychomycosis presentation: A patient presents with thickened, yellow-brown, crumbling toenails on one or both feet, often with concomitant tinea pedis. Diagnosis is confirmed by KOH preparation, fungal culture, or PCR assay — clinical appearance alone carries a false-positive rate as high as 50%, a figure supported by mycology literature cited by the AAD.

Nail psoriasis: Up to 90% of patients with psoriatic arthritis develop nail involvement, according to the National Psoriasis Foundation. Pitting is the most frequent finding; dactylitis (sausage digit) may co-occur.

Subungual melanoma: Constitutes 0.7–3.5% of all melanomas in white patients but a disproportionately higher percentage in patients with darker skin tones, as documented in the Journal of the American Academy of Dermatology. Longitudinal melanonychia is the hallmark. The ABCDEFs of subungual melanoma (Age, Band breadth ≥3 mm, Color variegation, Digit — thumb/hallux predominance, Extension to nail fold, Family history) guide dermoscopic evaluation. Dermatology resources covering skin cancer types and warning signs provide additional classification detail.

Paronychia: Acute paronychia is a bacterial infection (most commonly Staphylococcus aureus) of the proximal or lateral nail fold; chronic paronychia typically involves yeast overgrowth combined with repeated moisture exposure, classifying it as a distinct entity from the acute form.

Decision boundaries

The threshold for specialist referral, laboratory confirmation, or nail biopsy is governed by clinical criteria rather than patient preference. The following structured framework reflects published AAD and CDC guidance on nail pathology workup:

  1. Biopsy indicated — Any longitudinal melanonychia with band width ≥3 mm, irregular pigmentation, or Hutchinson sign (periungual pigment spread); any firm subungual mass; any nail change unresponsive to 6 months of appropriate treatment.
  2. Laboratory confirmation required before systemic antifungal treatment — Due to hepatotoxicity risk from oral terbinafine and itraconazole, the FDA and AAD position statements require mycological confirmation before initiating systemic therapy. A negative KOH with high clinical suspicion warrants culture or PCR before prescription.
  3. Systemic disease workup — New clubbing, koilonychia, or Beau's lines with no identifiable precipitant require internal medicine evaluation to rule out cardiopulmonary, hematologic, or endocrine pathology.
  4. Dermoscopy threshold — Any pigmented nail band in patients with Fitzpatrick skin types IV–VI warrants onychoscopy by a trained dermatologist, given the elevated relative prevalence of subungual melanoma in these populations.
  5. Topical-only management — Mild distal-lateral subungual onychomycosis involving fewer than 50% of the nail plate surface, with 1–3 nails affected and no matrix involvement, is a candidate for topical antifungal monotherapy (efinaconazole, tavaborole) per AAD Clinical Practice Guidelines.

The full regulatory and licensure framework governing dermatological procedures, including nail biopsy and prescription antifungal protocols, is detailed in the regulatory context for dermatology section of this resource.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)